170 related articles for article (PubMed ID: 32204943)
21. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
[TBL] [Abstract][Full Text] [Related]
24. Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials.
Huang Y; Williamson BD; Moodie Z; Carpp LN; Chambonneau L; DiazGranados CA; Gilbert PB
J Infect Dis; 2022 Jan; 225(2):332-340. PubMed ID: 34174082
[TBL] [Abstract][Full Text] [Related]
25. Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia.
Qi L; Sun Y; Juraska M; Moodie Z; Magaret CA; Heng F; Carpp LN; Gilbert PB
Vaccine; 2022 Sep; 40(41):5912-5923. PubMed ID: 36068106
[TBL] [Abstract][Full Text] [Related]
26. Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.
El Fezzazi H; Branchu M; Carrasquilla G; Pitisuttithum P; Perroud AP; Frago C; Coudeville L
Am J Trop Med Hyg; 2017 Dec; 97(6):1898-1903. PubMed ID: 29141713
[TBL] [Abstract][Full Text] [Related]
27. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.
Dorigatti I; Aguas R; Donnelly CA; Guy B; Coudeville L; Jackson N; Saville M; Ferguson NM
Vaccine; 2015 Jul; 33(31):3746-51. PubMed ID: 26051515
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series.
Park J; Archuleta S; Oh MH; Shek LP; Jin J; Bonaparte M; Fargo C; Bouckenooghe A
Hum Vaccin Immunother; 2020 Mar; 16(3):523-529. PubMed ID: 31464558
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
[TBL] [Abstract][Full Text] [Related]
31. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
Gessner BD; Wilder-Smith A
Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
[TBL] [Abstract][Full Text] [Related]
32. Zika and Dengue Interactions in the Context of a Large Dengue Vaccine Clinical Trial in Latin America.
Zambrano B; Noriega F; Dayan GH; Rivera DM; Arredondo JL; Reynales H; Luz K; Deseda C; Bonaparte MI; Langevin E; Wu Y; Cortés M; Savarino S; DiazGranados CA
Am J Trop Med Hyg; 2021 Jan; 104(1):136-144. PubMed ID: 33169661
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
Hadinegoro SR; Arredondo-García JL; Capeding MR; Deseda C; Chotpitayasunondh T; Dietze R; Muhammad Ismail HI; Reynales H; Limkittikul K; Rivera-Medina DM; Tran HN; Bouckenooghe A; Chansinghakul D; Cortés M; Fanouillere K; Forrat R; Frago C; Gailhardou S; Jackson N; Noriega F; Plennevaux E; Wartel TA; Zambrano B; Saville M;
N Engl J Med; 2015 Sep; 373(13):1195-206. PubMed ID: 26214039
[TBL] [Abstract][Full Text] [Related]
34. Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
Yang Y; Meng Y; Halloran ME; Longini IM
Clin Infect Dis; 2018 Jan; 66(2):178-184. PubMed ID: 29020332
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
[TBL] [Abstract][Full Text] [Related]
36. Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.
Park J; Archuleta S; Oh MH; Shek LP; Wang H; Bonaparte M; Frago C; Bouckenooghe A; Jantet-Blaudez F; Begue S; Gimenez-Fourage S; Pagnon A
Hum Vaccin Immunother; 2021 Jul; 17(7):2107-2116. PubMed ID: 33626291
[TBL] [Abstract][Full Text] [Related]
37. Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prospective, population-based cohort study.
Ylade M; Crisostomo MV; Daag JV; Agrupis KA; Cuachin AM; Sy AK; Kim DR; Ahn HS; Escoto AC; Katzelnick LC; Adams C; White L; de Silva AM; Deen J; Lopez AL
Lancet Infect Dis; 2024 Jul; 24(7):737-745. PubMed ID: 38527474
[TBL] [Abstract][Full Text] [Related]
38. Symptomatic Dengue in Children in 10 Asian and Latin American Countries.
L'Azou M; Moureau A; Sarti E; Nealon J; Zambrano B; Wartel TA; Villar L; Capeding MR; Ochiai RL; ;
N Engl J Med; 2016 Mar; 374(12):1155-66. PubMed ID: 27007959
[TBL] [Abstract][Full Text] [Related]
39. Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials.
Juraska M; Magaret CA; Shao J; Carpp LN; Fiore-Gartland AJ; Benkeser D; Girerd-Chambaz Y; Langevin E; Frago C; Guy B; Jackson N; Duong Thi Hue K; Simmons CP; Edlefsen PT; Gilbert PB
Proc Natl Acad Sci U S A; 2018 Sep; 115(36):E8378-E8387. PubMed ID: 30127007
[TBL] [Abstract][Full Text] [Related]
40. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America.
Arredondo-García JL; Hadinegoro SR; Reynales H; Chua MN; Rivera Medina DM; Chotpitayasunondh T; Tran NH; Deseda CC; Wirawan DN; Cortés Supelano M; Frago C; Langevin E; Coronel D; Laot T; Perroud AP; Sanchez L; Bonaparte M; Limkittikul K; Chansinghakul D; Gailhardou S; Noriega F; Wartel TA; Bouckenooghe A; Zambrano B;
Clin Microbiol Infect; 2018 Jul; 24(7):755-763. PubMed ID: 29408333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
